Bellerophon Therapeutics, Inc. (NASDAQ:BLPH) Sees Significant Growth in Short Interest

Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) was the target of a significant growth in short interest during the month of October. As of October 31st, there was short interest totalling 27,900 shares, a growth of 67.1% from the October 15th total of 16,700 shares. Based on an average daily volume of 16,800 shares, the days-to-cover ratio is currently 1.7 days. Approximately 0.3% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Bellerophon Therapeutics stock. Sepio Capital LP bought a new stake in shares of Bellerophon Therapeutics, Inc. (NASDAQ:BLPHGet Rating) in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund bought 23,800 shares of the biotechnology company’s stock, valued at approximately $29,000. Sepio Capital LP owned 0.25% of Bellerophon Therapeutics at the end of the most recent reporting period. 11.92% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

Separately, began coverage on shares of Bellerophon Therapeutics in a report on Sunday. They issued a “sell” rating on the stock.

Bellerophon Therapeutics Price Performance

Shares of BLPH opened at $1.10 on Monday. The firm has a market capitalization of $10.50 million, a PE ratio of -0.56 and a beta of 0.01. Bellerophon Therapeutics has a 1-year low of $0.67 and a 1-year high of $3.90. The company’s fifty day moving average price is $1.13 and its 200-day moving average price is $1.18.

Bellerophon Therapeutics (NASDAQ:BLPHGet Rating) last announced its quarterly earnings data on Monday, August 15th. The biotechnology company reported ($0.43) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.18. As a group, research analysts anticipate that Bellerophon Therapeutics will post -2.21 EPS for the current fiscal year.

Bellerophon Therapeutics Company Profile

(Get Rating)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Further Reading

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with's FREE daily email newsletter.